Company Situation - The company completed a general authorization placement of 58.4408 million new H-shares in January 2026, raising approximately HKD 1.319 billion, with a placement price of HKD 22.82, reflecting an 8.5% discount to the previous closing price. The funds are intended for laboratory and production facility construction, debt repayment, and working capital supplementation, which may impact the equity structure and short-term liquidity [2] Performance and Operating Conditions - The company announced on January 13, 2026, that it expects total revenue for 2025 to be between RMB 13.872 billion and RMB 14.24 billion, representing a year-on-year growth of 13% to 16%. However, the net profit attributable to the parent company is expected to decline by 6% to 10% year-on-year, primarily due to a decrease in non-recurring gains and losses. The net profit excluding non-recurring items is projected to increase by 36% to 41%, indicating an enhancement in the profitability of the main business [3] Industry and Risk Analysis - The CXO industry is experiencing intensified competition, with domestic leaders such as WuXi AppTec and Kelun Pharmaceutical, as well as international companies like Lonza, accelerating their market presence. This competitive landscape may exert pressure on the company's market share and pricing strategies. The company needs to address these challenges through capacity release and strategic acquisitions, such as the acquisition of Wuxi Bai'ao in November 2025 [4]

中访网数据 广发证券股份有限公司于2026年1月14日发布翌日披露报表，宣布其H股配售计划已完成。 根据公告，公司于2026年1月14日成功配发及发行2.19亿股新H股，每股发行价格为18.15港元。此次配 售完成后，广发证券的H股总数由约17.02亿股增加至约19.21亿股，占配售前现有已发行H股总数的比例 约为12.87%。与此同时，公司的A股数量保持不变，仍为约59.04亿股。因此，公司的总股本（包括A股 和H股）由配售前的约76.06亿股增加至约78.25亿股。此次股份变动是基于公司董事会此前的授权，并 遵循了所有适用的上市规则及监管规定。配售所得款项将用于补充公司资本金，支持业务发展，进一步 提升市场竞争力和抗风险能力。 来源：中访网 ...

Group 1 - The company, UBTECH, announced an agreement with placement agents to issue 31.468 million new H-shares at a price of HKD 98.80 per share, representing a discount of approximately 11.39% compared to the closing price on November 24, 2025 [1] - The net proceeds from the placement are approximately HKD 3.056 billion, with 75% intended for investments or acquisitions in target companies within the value chain or related industry consolidation/joint ventures [1] - 15% of the proceeds will be used for business operations and development, while 10% will be allocated to repay credit facilities from financial institutions [1]

Core Viewpoint - Guangfa Securities reported better-than-expected results for Q3 2025, with significant growth in revenue and net profit driven by brokerage and investment business income, alongside steady growth in asset management [1][2]. Group 1: Financial Performance - For the first nine months of 2025, Guangfa Securities achieved operating revenue of 26.16 billion, a year-on-year increase of 41.0%, and a net profit attributable to shareholders of 10.93 billion, up 61.6% year-on-year [1]. - The weighted average ROE (unannualized) for the same period was 8.18%, an increase of 2.92 percentage points year-on-year [1]. - The breakdown of revenue for 9M25 shows brokerage, investment banking, asset management, net interest, and net investment income at 6.98 billion, 0.52 billion, 5.66 billion, 1.69 billion, and 9.36 billion respectively, with year-on-year changes of +75.0%, -3.0%, +11.4%, +23.1%, and +56.9% [1]. - In Q3 2025, net profit reached 4.46 billion, reflecting an 85.9% year-on-year increase and a 20.3% quarter-on-quarter increase [1]. Group 2: Capital and International Business Development - The company plans to issue up to 340 million H shares to supplement capital and enhance international business development [2]. - As of Q3 2025, the company's operating leverage was 4.76x, which is 1.31x higher than the average of listed brokers, indicating a need for capital replenishment [2]. - The capital adequacy ratio was reported at 11.2%, with a liquidity coverage ratio of 141.9% [2]. Group 3: Investment and Asset Management - By the end of Q3 2025, the company's investment leverage was 3.18x, with financial investment scale reaching 487.8 billion, a 30.6% increase year-to-date [3]. - The net investment income for Q3 2025 was 4.12 billion, showing a year-on-year increase of 79.4% [3]. - The asset management business revenue for Q3 2025 was 1.99 billion, up 17.3% year-on-year [4]. - The non-monetary AUM of Guangfa Fund reached 991.3 billion, a 17.8% increase year-to-date, ranking third in the industry [4]. Group 4: Brokerage and Market Performance - The brokerage business generated revenue of 3.06 billion in Q3 2025, reflecting a year-on-year increase of 149.3% [4]. - The company's margin financing and securities lending market share was reported at 5.7%, a slight decrease of 0.14 percentage points year-on-year [4]. Group 5: Future Profit Projections - Expected net profits for Guangfa Securities for 2025, 2026, and 2027 are projected at 14.21 billion, 15.83 billion, and 16.78 billion respectively, with year-on-year growth rates of +47.5%, +11.4%, and +6.0% [5].

Group 1 - Ganfeng Lithium (002460) has completed a placement of 40.0256 million new H-shares at a price of HKD 29.28 per share, representing 9.02% of the enlarged issued H-shares [1] - The total amount raised from the placement is approximately HKD 1.172 billion, with a net amount of about HKD 1.1685 billion after deducting commissions and estimated expenses [1] - The placement was made to no less than six independent professional or institutional investors, with no major shareholders emerging post-placement [1] Group 2 - The initial conversion price for the bonds is set at HKD 33.67 per H-share, which is subject to adjustment [2] - If the bonds are fully converted at the initial conversion price, they will convert into approximately 40.689 million H-shares, representing about 9.17% of the enlarged issued H-shares and 1.98% of the total issued shares [2] - After full conversion of the bonds, the total number of issued H-shares will increase by approximately 8.40% and the total issued share capital by about 1.94% [2]

Core Viewpoint - Ganfeng Lithium (1772.HK) plans to issue new H-shares, expecting total proceeds of approximately HKD 1.171 billion, with the placement price set at HKD 29.28 per share, representing a discount of 5.49% from the latest closing price [1] Summary by Categories - **Fundraising Details** - The total amount expected from the share placement is approximately HKD 1.171 billion [1] - The placement price is set at HKD 29.28 per share, which is a 5.49% discount compared to the latest closing price [1] - **Use of Proceeds** - The proceeds from the share placement will be used for loan repayment, capacity expansion and construction, working capital replenishment, and general corporate purposes [1]

Core Viewpoint - The company has approved a plan to issue H-shares and convertible bonds to enhance its logistics capabilities and optimize its capital structure [1][10]. Group 1: H-Share Placement - The company plans to issue up to 70,000,000 H-shares, representing a maximum of 10% of the total shares issued as of June 13, 2025 [3][10]. - The shares will be offered to qualified investors independent of the company and its affiliates, with the pricing determined based on market conditions [3][5]. - The net proceeds from the H-share placement will be used to strengthen international logistics capabilities, develop advanced technologies, and optimize the company's capital structure [7][10]. Group 2: Convertible Bond Issuance - The company intends to issue up to HKD 2.95 billion in convertible bonds through its wholly-owned subsidiary, SF Holding Investment 2023 Limited [11][12]. - The bonds will be zero-coupon, with a maturity date of July 8, 2026, and will be convertible into H-shares [14][15]. - The proceeds from the bond issuance will also be allocated to enhancing logistics capabilities and optimizing the capital structure [16][22]. Group 3: Authorization Matters - The board has authorized the company's vice president and financial officer to handle all matters related to the H-share placement and convertible bond issuance [5][17]. - The authorization includes obtaining necessary approvals from regulatory bodies and finalizing agreements related to the offerings [6][18]. - The validity of the board's resolutions is set for three months for the H-share placement and twelve months for other authorization matters [9][22].